Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tallikut Pharmaceuticals, Inc.
With
Montreal Heart Institute
This is a Phase II, randomized, double-blind, placebo-controlled study of the effect of VIA-2291 on atherosclerotic vascular inflammation
Age
30–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Female patients are to be of non-childbearing potential
Patient has suffered an ST elevation myocardial infarction (MI), non-ST elevation MI, or unstable angina 21 days (±3 days) prior to study randomization
Patient has documented coronary artery disease
You may not be if
Renal insufficiency defined as creatinine \>1.5 x upper limit of normal (ULN)
Cirrhosis, recent hepatitis, ALT \>1.5 x ULN or ALT \> 1 x ULN and at least one other liver function test
Uncontrolled diabetes mellitus within 1 month prior to study screening
Congestive heart failure (CHF) defined by the New York Heart Association as functional Class III or IV
Previous coronary artery bypass graft (CABG) surgery
Planned additional cardiac intervention
Recurrence of ST elevation MI, non-ST elevation MI, or unstable angina less than 18 days prior to randomization
Current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions
Acetaminophen use in any form in the 7 days before enrollment
Clareo Health | Study Effect of VIA-2291 on Vascular Inflammation
